ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of “Hold” from Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have earned a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.6667.

A number of equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group cut their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Raymond James Financial began coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Zacks Research downgraded ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 4th.

ADMA Biologics Stock Up 0.6%

Shares of NASDAQ:ADMA opened at $9.47 on Friday. The stock’s 50-day moving average price is $8.81 and its two-hundred day moving average price is $11.04. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 13.53 and a beta of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 EPS. On average, research analysts forecast that ADMA Biologics will post 0.78 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of ADMA Biologics in the second quarter valued at $321,037,000. Janus Henderson Group PLC increased its stake in ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after buying an additional 3,838,158 shares during the period. Capital Research Global Investors increased its stake in ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after buying an additional 3,383,559 shares during the period. Caligan Partners LP acquired a new position in ADMA Biologics in the 3rd quarter worth $38,653,000. Finally, UBS Group AG lifted its holdings in ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after buying an additional 2,581,670 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.